These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12654259)

  • 21. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiangiogenic scheduling of lower dose cancer chemotherapy.
    Gately S; Kerbel R
    Cancer J; 2001; 7(5):427-36. PubMed ID: 11693902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy.
    Stoll BR; Migliorini C; Kadambi A; Munn LL; Jain RK
    Blood; 2003 Oct; 102(7):2555-61. PubMed ID: 12775571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
    van Moorselaar RJ; Voest EE
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
    Plavetić ND; Letilović T; Vrbanec D
    Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenic inhibitors: a new therapeutic strategy in oncology.
    Gasparini G; Longo R; Toi M; Ferrara N
    Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.
    Pisanti S; Borselli C; Oliviero O; Laezza C; Gazzerro P; Bifulco M
    J Cell Physiol; 2007 May; 211(2):495-503. PubMed ID: 17192847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor angiogenesis and therapy.
    Cao Y
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S340-3. PubMed ID: 16507405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The possible role of chemotherapy in antiangiogenic drug resistance.
    Bocci G; Loupakis F
    Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
    Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
    J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N
    Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance in the anti-angiogenic era: nay-saying or a word of caution?
    Sweeney CJ; Miller KD; Sledge GW
    Trends Mol Med; 2003 Jan; 9(1):24-9. PubMed ID: 12524207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.